AOD-9604
Shop AOD-9604AOD-9604 is not actually discussed in any of the pages used for this summary. These pages come from a clinic website about weight-loss medicines and general peptide therapy. AOD-9604 is a small protein fragment that was studied as a possible weight-loss drug. It is a piece copied from a larger hormone that the body uses to control how food is used and stored.
People interested in it usually want help losing weight or burning fat. In early studies, this fragment was thought to copy the fat-burning part of the larger hormone, but without effects on blood sugar or bone growth. The idea was that it could signal the body to break down fat while leaving other systems alone. The clinic pages do not list AOD-9604 among the treatments they offer, so nothing here confirms anyone actually uses it.
Important caution: there is very little strong human evidence for AOD-9604, and it was never approved as a medicine. Big studies did not show it worked well enough for weight loss. Because it is not approved, quality, safety, and dosing are not well controlled. Talk to a real doctor before considering anything like this.
Benefits
What AOD-9604 Helps With
The benefits people report — backed by research.
Weight management (11)
Glycemic & metabolic (5)
Antioxidant / oxidative stress (2)
Tissue & wound healing (2)
Musculoskeletal (2)
Free: The Peptide Stack Cheat-Sheet
You just read the research on AOD-9604. The cheat-sheet maps the most-used peptide stacks — doses, timing, and what to check before buying — on one page.
No spam. Unsubscribe anytime.
How People Use It
1 reported routine — each line links to the source it came from.
From published sources
Routines as reported in peer-reviewed papers, clinical guidance, or vetted media — each linked to the source it came from.
SubQ
- Chronic ip administration for 14 days (specific dose not mentioned in text) 85/100Rated 85/100Source typePeer-reviewed studyIndependent sources4Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ source
mg vs mcg: one milligram (mg) equals 1,000 micrograms (mcg) — multiply by 1,000 going from mg to mcg, divide by 1,000 going from mcg to mg. Mixing the two up is a thousand-fold dosing error: 1 mg taken instead of 1 mcg is a 1,000× overdose; 1 mcg instead of 1 mg is a 1,000× underdose. Always double-check the unit label and the decimal place.
Honest expectations
What AOD-9604 doesn’t do
What the sourced research says it doesn’t do — as notable as what it does.
- Fat loss without IGF-1 elevation 60/100Rated 60/100Source typeSpecialist communityIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↵ source
- AOD-9604 demonstrated fat reduction without affecting IGF-1 or glucose levels 60/100Rated 60/100Source typeSpecialist communityIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↵ source
- AOD-9604 demonstrated fat reduction without affecting IGF-1 or glucose levels (Phase 2b) 60/100Rated 60/100Source typeSpecialist communityIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↵ source
Safety
Known Side Effects
Adverse effects reported in the research and by community use.
- Mild injection-site reactionsMildReported in 2 sources 60/100Rated 60/100Source typeSpecialist communityIndependent sources2Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ peptidepedia.org↗ peptide-db.com
- Occasional mild headachesMild 60/100Rated 60/100Source typeSpecialist communityIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ peptidepedia.org
- Transient fatigue during the initial days of useMild 60/100Rated 60/100Source typeSpecialist communityIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ peptidepedia.org
- Injection-site reactionsMildReported in 2 sources 60/100Rated 60/100Source typeSpecialist communityIndependent sources2Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ peptidepedia.org↗ peptidepedia.org
- FatigueMildReported in 2 sources 60/100Rated 60/100Source typeSpecialist communityIndependent sources2Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ peptidepedia.org↗ peptidedosingprotocols.com
- NauseaModerateReported in 15 sources 60/100Rated 60/100Source typeSpecialist communityIndependent sources15Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ peptidepedia.org↗ canada.pharmalabglobal.com↗ america.pharmalabglobal.com↗ netherlands.pharmalabglobal.com+11
- DiarrheaMildReported in 3 sources 60/100Rated 60/100Source typeSpecialist communityIndependent sources3Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ peptidepedia.org↗ utherpeptide.com↗ peptidedosingprotocols.com
- VomitingModerateReported in 2 sources 60/100Rated 60/100Source typeSpecialist communityIndependent sources2Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ peptidepedia.org↗ utherpeptide.com
- ConstipationMild 60/100Rated 60/100Source typeSpecialist communityIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ peptidepedia.org
Reported in research and community sources — not exhaustive. Discontinue use and consult a healthcare professional if side effects occur.
Get AOD-9604
Compare research-grade suppliers with third-party COAs and published purity data. For in-vitro and laboratory research use only — not for human consumption, diagnosis, or treatment.
Technical Details (sequence & mechanism — click to expand)
Amino Acid Sequence
Mechanism of Action
AOD-9604 is a synthetic peptide corresponding to the C-terminal lipolytic fragment of human growth hormone (aa 177-191). It stimulates lipolysis and inhibits lipogenesis in adipose tissue - promoting fat oxidation and weight loss in animals - without affecting IGF-1 or glucose metabolism. It reached phase-II human trials but was not approved as an anti-obesity drug due to modest efficacy.
Evidence
Research Citations (4)
Every claim above traces back to a source you can check — here are 4 of them.
- Source
The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice.
AnimalStudy2001 Key study 82/100Rated 82/100Source typePeer-reviewed studyIndependent sourcesstill being verifiedEvery claim links to the page it came from, and stronger sources rate higher. Full methodology → - Source
AOD-9604 Metabolic.
2004 95/100Rated 95/100Source typePeer-reviewed studyIndependent sourcesstill being verifiedEvery claim links to the page it came from, and stronger sources rate higher. Full methodology → - Source
AOD-9604 does not influence the WADA hGH isoform immunoassay.
2013 95/100Rated 95/100Source typePeer-reviewed studyIndependent sourcesstill being verifiedEvery claim links to the page it came from, and stronger sources rate higher. Full methodology → - Source
PubChem - Compound - AOD9604 acetate
95/100Rated 95/100Source typePeer-reviewed studyIndependent sourcesstill being verifiedEvery claim links to the page it came from, and stronger sources rate higher. Full methodology →
Timeline
History & Milestones
Key moments in AOD-9604’s research and regulatory timeline — sourced and dated.
- The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolismPublicationDec 1, 2001Related:AOD-9604
- The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice.PublicationDec 1, 2001Related:AOD-9604
- Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormonePublicationJan 1, 2000Related:AOD-9604
News
Latest on AOD-9604
Dated, sourced reporting that mentions AOD-9604.
Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks
FDA's running list of bulk drug substances that present significant safety risks in compounding names GHRP-2, GHRP-6, ipamorelin acetate, CJC-1295 and AOD-9604. GHRP-2 and GHRP-6 were added to the 503B risk list on September 29, 2023 over immunogenicity concerns, and FDA notes serious adverse events for CJC-1295 (increased heart rate, systemic vasodilatory reactions). The list confirms these peptides are treated by FDA as unsafe-for-compounding substances.
Tailor Made Compounding LLC
FDA warned Tailor Made Compounding LLC (Nicholasville, KY) after a 2018 inspection found it compounded drug products with bulk substances ineligible for 503A exemptions. The letter explicitly lists the compounded substances: Follistatin, GHRP-2, GHRP-6, AOD 9604, BPC 157, Bremelanotide (PT-141), Cerebrolysin, DSIP, Epitalon, GHK-Cu, Ipamorelin, LL-37, Melanotan II, Selank, Semax, and CJC 1295, among others. The firm was cited for insanitary aseptic processing (adulteration), unapproved new drugs, and misbranding, and removed GHRP-2 and GHRP-6 from its formulary in response.
Wondering how AOD-9604 pricing compares across suppliers? Our original market data shows the full picture.
See the State of the Peptide Market 2026 →Related on The Health Stacks
Explore by goal
Related peptides